Fibroblast Growth Factor 12 Is a Novel Regulator of Vascular Smooth Muscle Cell Plasticity and Fate
- 문서 유형
- 연구출판물 · 학술지 논문
- 등재
- SCIEScopus
- 저널 순위
- JCR Q1Scopus Q1
- 저널
- ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY36(9) · pp.1928 · 2016
- 피인용
- Web of Science 33
- JCR IF
- JCR 2015 5.969
- ISSN
- 1079-5642
저자
- Song, Sun-Hwa제1저자College of Pharmacy, Chung-Ang University, Dongjak-Gu, Seoul, South Korea
- Kim, KyungjongCollege of Pharmacy, Chung-Ang University, Dongjak-Gu, Seoul, South Korea
- Jo, Eun-KyungCollege of Pharmacy, Chung-Ang University, Dongjak-Gu, Seoul, South Korea
- Kim, Young-WookDivision of Vascular Surgery, Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea
- Kwon, Jin-SookDivision of Cardiovascular and Rare Disease, Center for Biomedical Sciences, Korea National Institute of Health, Osong, Cheongju, Chungbuk, South Korea
- 배순식Department of Pharmacology, School of Medicine, Pusan National University, Yangsan, Gyeongnam, South Korea
- Sung, Jong-HyukCollege of Pharmacy, Yonsei University, Incheon, South Korea
- Park, Sang GyuCollege of Pharmacy, Ajou University, Suwon, South Korea
- Kim, Jee TaekDepartment of Ophthalmology, College of Medicine, Chung-Ang University, Seoul, South Korea
- Suh, Wonhee교신저자College of Pharmacy, Chung-Ang University, Dongjak-Gu, Seoul, South Korea
초록
Objective Vascular smooth muscle cells (VSMCs) modulate their phenotype between synthetic and contractile states in response to environmental changes; this modulation plays a crucial role in the pathogenesis of restenosis and atherosclerosis. Here, we identified fibroblast growth factor 12 (FGF12) as a novel key regulator of the VSMC phenotype switch. Approach and Results Using murine models and human specimens, we found that FGF12 was highly expressed in contractile VSMCs of normal vessel walls but was downregulated in synthetic VSMCs from injured and atherosclerotic vessels. In human VSMCs, FGF12 expression was inhibited at the transcriptional level by platelet-derived growth factor-BB. Gain- and loss-of-function experiments showed that FGF12 was both necessary and sufficient for inducing and maintaining the quiescent and contractile phenotypes of VSMCs. FGF12 inhibited cell proliferation through the p53 pathway and upregulated the key factors involved in VSMC lineage differentiation, such as myocardin and serum response factor. Such FGF12-induced phenotypic change was mediated by the p38 MAPK (mitogen-activated protein kinase) pathway. Moreover, FGF12 promoted the differentiation of mouse embryonic stem cells and the transdifferentiation of human dermal fibroblasts into SMC-like cells. Furthermore, adenoviral infection of FGF12 substantially decreased neointima hyperplasia in a rat carotid artery injury model. Conclusions In general, FGF family members induce a synthetic VSMC phenotype. Interestingly, the present study showed the unanticipated finding that FGF12 belonging to FGF family, strongly induced the quiescent and contractile VSMC phenotypes and directly promoted VSMC lineage differentiation. These novel findings suggested that FGF12 could be a new therapeutic target for treating restenosis and atherosclerosis.
키워드
cell proliferationcell transdifferentiationmusclesmoothvascularmyocytessmooth muscleneointimaFACTOR HOMOLOGOUS FACTORSACTIVATED PROTEIN-KINASESERUM RESPONSE FACTORGENE-EXPRESSIONDIFFERENTIATIONMODULATIONMIGRATIONPROLIFERATIONTRANSCRIPTIONINHIBITION
식별자
- WoS UID
- 000383582900029



로그인
연구물 목록으로